ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2738

The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients

Mark Berman1, Daphna Paran1, Yonatan Wolman1 and Ori Elkayam2, 1Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-TNF therapy, Disease Activity, pregnancy, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on disease activity, has not been well studied. The aim of this study is to evaluate the effect of pregnancy on disease activity in PsA

Methods:  A retrospective review of files of female patients followed at the Psoriatic arthritis clinic at the Tel Aviv Medical center was performed and patients with at least 1 pregnancy during follow up and one visit during or soon after pregnancy were included in this descriptive study. A thorough review of the files was performed which included the following data: age, disease duration, pattern of PsA, disease activity before during and after pregnancy, record of treatment, including IA injections before and during pregnancy. Postpartum period was defined as up to 1 year after pregnancy. PsA as well as psoriasis activity was defined by treating physician as follow: no disease activity (no active synovitis), mild disease (up to 1 joint involved), moderate to severe disease (more than 2 joints involved). Accordingly, the follow up during and after pregnancy was classified as: improvement, worsening or stable

Results:  13 PsA women and 20 pregnancies were identified. 19 resulted in live healthy babies. The mean age at pregnancy was 31.6 years. Table 1 summarizes the status of disease activity before, throughout pregnancy and during the postpartum period in the whole group. No significant change in disease activity was noticed throughout pregnancy while a significant proportion of patients flared at postpartum Before 12 pregnancies, the patients were treated with TNF α blockers. In 10, the biologic treatment was discontinued close to pregnancy or during the first trimester. In this group, 4 (40%) of patients were classified as mild to severe activity prior to pregnancy. This number increased up to 6 (60%), 7 (70%) and 10 (100%) during the 1st, 2nd trimester and postpartum period respectively. In the 2 patients in whom biologics were not stopped pregnancy, no change in the degree of disease activity was noticed. Interestingly, in the group of non-TNFα treated patients, an improvement in disease activity was observed – the proportion of patients with mild to severe disease activity decreased from 100% close to pregnancy to 71% in the 1st and 2nd trimester and 43% in the 2rd one while an increase to 86% was observed after pregnancy. During 5 pregnancies, corticosteroids were initiated or dosage increased – all in pregnancies where TNF α blockers were stopped before pregnancy. Table 1. Disease activity during pregnancy

No (%)

Before pregnancy

Trimester

Post partum

1st

2nd

3rd

No disease activity

7 (37%)

6 (32%)

6 (32%)

8 (42%)

2 (10%)

Mild dis. Activity

4 (21%)

5 (26%)

5 (26%)

5 (26%)

6 (32%)

Moderate to severe dis. Activity

8 (42%)

8 (42%)

8 (42%)

4 (21%)

11 (58%)

Conclusion:  Patients with PsA definitively flare after pregnancy. Our results suggest that stopping treatment with TNF α blockers before pregnancy is associated with flare during pregnancy and the postpartum period. It seems that in terms of PsA disease activity, it is recommended to continue treatment with TNF α blockers throughout pregnancy


Disclosure: M. Berman, None; D. Paran, None; Y. Wolman, None; O. Elkayam, None.

To cite this abstract in AMA style:

Berman M, Paran D, Wolman Y, Elkayam O. The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-effect-of-pregnancy-on-disease-activity-outcomes-in-psoriatic-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-pregnancy-on-disease-activity-outcomes-in-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology